Potential factors influencing carbapenem activity against Bacteroides fragilis group isolates.
Iaconis
J P
JP
Zeneca Pharmaceuticals Group, Wilmington, Delaware 19897, USA.
Nadler
H L
HL
Sheikh
W
W
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001425:Bacterial Outer Membrane Proteins / Q000032:analysis; D001441:Bacteroides fragilis / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D015780:Carbapenems / Q000494:pharmacology*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D013845:Thienamycins / Q000494:pharmacology; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001425:Bacterial Outer Membrane Proteins; D015780:Carbapenems; D013845:Thienamycins; D015378:Imipenem; D001618:beta-Lactamases; D000077731:Meropenem